Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30162

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

LONG-TERM EFFICACY AND SAFETY OF RALTEGRAVIR COMBINED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENT-EXPERIENCED PATIENTS WITH DRUG-RESISTANT HIV INFECTION: WEEK 96 RESULTS OF THE BENCHMRK 1 AND 2 PHASE III TRIALS
Steigbigel, Roy T. et al. | Date Issued: 2010
Author
Steigbigel, Roy T.
Cooper, David A.
Teppler, Hedy
Eron, Joseph J.
Gatell, Jose M.
Kumar, Princy N.
Rockstroh, Jurgen K.
Schechter, Mauro
Katlama, Christine
Markowitz, Martin
Yeni, Patrick
Loutfy, Mona R.
Lazzarin, Adriano
Lennox, Jeffrey L.
Clotet, Bonaventura
Zhao, Jing
Wan, Hong
Rhodes, Rand R.
Strohmaier, Kim M.
Barnard, Richard J.
Isaacs, Robin D.
Nguyen, Bach-Yen T.
BENCHMRK Study Team
Affilliation
State University of New York. Stony Brook, USA.
University of New South Wales. National Centre in HIV Epidemiology and Clinical Research. Sydney, Australia.
Merck Research Laboratories. North Wales, Pennsylvania, USA.
University of North Carolina. Chapel Hill, USA.
Universidad de Barcelona. Hospital Clinic-IDIBAPS. Barcelona, España.
Georgetown University Medical Center. Washington, DC, USA.
University of Bonn. Department of Medicine I. Bonn, Germany.
Universidade Federal do Rio de Janeiro. Rio de Janeiro, Brasil.
Université Pierre et Marie Curie. Hospital Pitié Salpêtrière. Paris, France.
The Rockefeller University. Aaron Diamond Research Center. New York, NY, USA.
Hospital Bichat-Claude Bernard. Paris, France.
University of Toronto. Toronto, ON, Canada.
San Raffaele Scientific Institute. Milan, Italy.
Emory University School of Medicine. Atlanta, GA, USA.
Universitat Autònoma de Barcelona. Fundación Irsicaixa. Hospital Germans Trias i Pujol. Barcelona, España.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Merck Research Laboratories. North Wales, PA, USA.
Abstract
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
Keywords
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Therapy
Drug Resistance
Pyrrolidinones
Raltegravir Potassium
HIV-1
 
Citation
STEIGBIGEL, R. T .et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clinical infectious diseases, v. 50, n. 4, p. 605-612, 2010.
DOI
10.1086/650002
ISSN
1058-4838
Notes
Presente no BENCHMRK Study Teams: Beatriz Grinsztejn (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil).